Status:
RECRUITING
EULAT Eradicate GBC
Lead Sponsor:
Institut de cancérologie Strasbourg Europe
Collaborating Sponsors:
Heidelberg University Hospital (UKHD, Germany, Coordinator)
Universidad Austral de Chile (UACH, Chile)
Conditions:
Gallbladder Cancer
Gallstone Disease
Eligibility:
All Genders
18+ years
Brief Summary
Gallstones are relatively frequent in women and constitute one of the main risk factors for gallbladder cancer (GBC). Currently, GBC diagnosis is mainly based on imaging (ultrasound or abdominal CT) ...
Detailed Description
Gallbladder cancer (GBC) is a neglected disease with huge potential for prevention. This study aims at significantly improving the accuracy of risk estimation and early detection of GBC by identifying...
Eligibility Criteria
Inclusion
- Cohort A. Patients with gallbladder cancer or dysplasia, both before and after the start of their anticancer treatment.
- Cohort B. Patients with cholelithiasis before cholecystectomy (only patients scheduled for cholecystectomy will be recruited)
- Diagnosis confirmed in accordance with standard protocols of the participating hospitals
- Men and women aged 18 or over
Exclusion
- Any medical condition that present an unreasonable risk to the participant.
- Any psychiatric condition that interferes with understanding informed consent.
Key Trial Info
Start Date :
December 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2028
Estimated Enrollment :
15000 Patients enrolled
Trial Details
Trial ID
NCT06192719
Start Date
December 1 2019
End Date
December 31 2028
Last Update
May 31 2024
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital Papa Francisco
Salta, Argentina
2
Sanatorio el Carmen
Salta, Argentina
3
Hospital Pablo Soria
San Salvador de Jujuy, Argentina
4
Complejo Hospitalario Viedma
Cochabamba, Bolivia